Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a two part study. The objective of Part 1 is to evaluate the safety, tolerability,
and pharmacokinetics of HT-2157 in healthy normal volunteers
Part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day) ascending-dose
evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HT-2157 in
patients with major depressive disorder